Citigroup Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Key Points

• Citigroup raised Merck’s price target to $145 from $125 but maintained a neutral rating; the new target implies roughly 0.33% downside from the stock’s $145.49 price. Analysts overall give Merck a “Moderate Buy” rating with an average target of $151.92.
• Merck exceeded quarterly expectations, reporting adjusted loss per share of $0.13 versus the $0.26 consensus loss, while revenue reached $16.61 billion, up 5.1% year over year. The company reaffirmed fiscal 2026 EPS guidance of $2.66–$2.76.
• Insiders have sold 228,238 shares worth nearly $30 million over the past 90 days, while institutional investors own 76.07% of the stock. Separately, Merck’s investigational remigromig met the non-inferiority threshold against Lucentis in a diabetic macular edema trial.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price objective upped by investment analysts at Citigroup from $125.00 to $145.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a "neutral" rating on the stock. Citigroup's target price would indicate a potential downside of 0.33% from the stock's current price.

MRK has been the subject of several other reports. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, August 20th. Royal Bank Of Canada lowered their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a "sector perform" rating on the stock in a report on Monday. Guggenheim lifted their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the company a "buy" rating in a research report on Tuesday, September 8th. Scotiabank lifted their price target on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a "sector outperform" rating in a research report on Tuesday, September 29th. Finally, JPMorgan Chase & Co. boosted their price objective on Merck & Co., Inc. from $150.00 to $165.00 and gave the stock an "overweight" rating in a report on Monday, October 5th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $151.92.

Merck & Co., Inc. Price Performance

Shares of MRK traded down $0.11 during mid-day trading on Monday, reaching $145.49. 6,615,526 shares of the stock traded hands, compared to its average volume of 10,634,951. The firm has a fifty day moving average price of $143.90 and a 200 day moving average price of $128.37. The company has a market cap of $358.94 billion, a price-to-earnings ratio of 116.39, a price-to-earnings-growth ratio of 6.58 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same quarter in the prior year, the firm posted $2.13 earnings per share. The business's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 10,000 shares of the company's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares in the company, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Large investors have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares during the period. State Street Corp increased its holdings in Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its stake in Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Bank of America Corp DE raised its stake in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares during the period. Finally, Invesco Ltd. raised its stake in Merck & Co., Inc. by 3.5% during the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company's stock worth $2,162,691,000 after acquiring an additional 701,249 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Remigromig met the trial’s statistical non-inferiority threshold versus Lucentis in diabetic macular edema, preserving a potential path for the investigational treatment. Merck Presents One-Year Results from the BRUNELLO Study

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.